News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
ESTRO CNS Focus Group survey
Photo taken from ESTRO/X
Sep 21, 2024, 19:06

ESTRO CNS Focus Group survey

ESTRO shared a post on X:

“Just a friendly reminder!

The deadline to complete the ESTRO CNS Focus Group survey on neuroprotective methods in radiation oncology for brain metastases is approaching fast.

Submit your insights by 30 September.”

Source: ESTRO/X

brain metastases cancer CNS Focus Group ESTRO neuroprotective methods OncoDaily Oncology radiation oncology
Special Coverage
Blog
May 9, 2025, 14:34
Maria Concetta La Milia: Patient-Reported Outcomes in Nose Vestibule Interventional Radiotherapy at ESTRO2025
Blog
May 9, 2025, 14:19
Josh Thomas Georgy Highlights DESTINY-Breast11 Results in High-Risk HER2+ Early Breast Cancer
Blog
May 9, 2025, 14:18
Half of Patients Diagnosed With Cancer in 2023 Had a History of Smoking - CRI
Blog
May 9, 2025, 14:08
Aligning Incentives for Value-Based Success: Building Sustainable Oncology Partnerships - CancerX
Blog
May 9, 2025, 14:06
Childhood Cancer at Survivor’s Week 2025: A Celebration of Strength and New Beginnings
Blog
May 9, 2025, 14:01
Meet the ASCO25 Featured Voices
Blog
May 9, 2025, 13:59
Arturo LoAIza-Bonilla: How AI and Digital Platforms are Transforming Patient Adherence and Real-Time Decision Support
Insight
May 9, 2025, 13:55
FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot
Blog
May 9, 2025, 13:49
Fernando Goldsztein: A Time to Raise Awareness about Brain Tumors
Blog
May 9, 2025, 13:46
Small Cell Lung Cancer Progress: Insights from LUNGevity's Executive Director
Blog
May 9, 2025, 13:37
Helena Linardou: Exciting afternoon at the 2025 AI for Oncology Congress
Opinion
May 9, 2025, 13:29
Galip Can Uyar: Prophylactic oophorectomy boosts survival by up to 50% in young women with BRCA mutations